GC Genome and MP Group have signed a collaboration and exclusive licence agreement for the commercialisation of the SNP genotyping service, Genome Health, in Thailand.
As per the agreement terms, MP Group will receive an exclusive licence from GC Genome to market Genome Health within the territory.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
GC Genome will transfer vital wet lab technology and know-how necessary for running a genetic laboratory in Thailand as part of this collaboration.
After receiving the technology, MP Group aims to introduce the product in the country as ‘genechecks’ and begin a marketing campaign for its promotion.
Genome Health leverages next-generation sequencing (NGS) for detecting risk alleles linked to major cancer types and general diseases.
GC Genome CEO Dr Chang-Seok Ki said: “Genome Health is actively securing a robust presence in South Korea’s genetic health checkup market, with a primary focus on disease-related health assessments.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“With the capability to analyse 45 diseases in a single test, our service ensures efficient and accurate personalised health management.”
The companies have also signed a memorandum of understanding (MoU) to further their collaboration in broadening the range of products developed by GC Genome.
This expansion involves the transfer of technology and covers various areas such as prenatal and neonatal health checkups, rare diseases and precision oncology in Thailand.
MP Group CEO Nathporn Boonbuppa said: “We are pleased to be partnering with GC Genome to extend the reach of our genetic technology platform and bring novel new product candidates forward with the potential to benefit Thai citizens.”
